Radiopharm Theranostics Limited registered up to 1,345,728 ADSs for resale from time to time by the Selling Shareholders, representing 403,718,400 ordinary shares issuable upon exercise of Warrants. Each ADS represents 300 ordinary shares.
The Selling Shareholders receive all proceeds from ADS sales. Radiopharm may receive up to approximately US$5.1 million upon exercise of Warrants issued to the Selling Shareholders.
Radiopharm Theranostics Ltd (RADX) furnished a Form 6-K providing Australian Appendix 3Y notices detailing changes in directors’ interests following participation in a Securities Purchase Plan approved at an extraordinary general meeting on September 11, 2026.
Director Bruce Goodwin now indirectly holds 2,777,778 shares and 2,777,778 options. Ian Turner holds 3,752,817 direct shares and 23,179,148 direct options, plus 9,010,253 indirect shares and 1,625,978 indirect options, totaling 12,763,070 shares and 24,805,126 options. Paul Hopper holds 53,900,000 direct shares and 26,142,000 direct options, plus 96,599,206 indirect shares and 11,795,296 indirect options, totaling 150,499,206 shares and 37,937,296 options. Riccardo Canevari holds 23,918,875 direct shares and 187,301,188 direct options, plus 2,650,000 indirect shares, totaling 26,568,875 shares and 187,301,188 options. No interests were traded during a closed period requiring prior written clearance.
Radiopharm Theranostics Limited (RADX) reported positive interim results from a U.S. Phase 2b imaging trial of its PET tracer 18F‑RAD101 in patients with suspected recurrent brain metastases. RAD101 PET showed 93% concordance with MRI across all evaluable lesions, meeting the study’s primary endpoint, and data have been selected for a late‑breaking oral presentation at the 2026 Society of Neuro‑Oncology meeting.
The company plans to meet the FDA on October 1, 2026 to align on the protocol for a pivotal, multi‑center global Phase 3 imaging trial, supported in the U.S. by a manufacturing and distribution partnership with Siemens Healthineers. Preliminary analysis in 14 patients with six‑month follow‑up and/or biopsy showed 86% sensitivity, a secondary objective, in a U.S. market the company estimates at about $600 million for brain metastases imaging with no currently approved PET products.
Radiopharm Theranostics Limited (RADX) has filed a Form F-3 to register for resale up to 1,345,728 American Depositary Shares, representing 403,718,400 ordinary shares, issuable upon exercise of warrants held by selling shareholders from a July 2026 private placement. The ADSs trade on Nasdaq under “RADX” and each ADS represents 300 ordinary shares. The selling shareholders will receive all proceeds from any ADS resales; Radiopharm will not receive sale proceeds but may receive up to US$5.1 million if the registered warrants are exercised, and will also receive proceeds from any option exercises. The F-3 also describes the July 2026 private placement that raised approximately US$3.3 million and an additional Australian placement raising A$6.7 million, and presents an adjusted capitalization table as of December 31, 2025 showing higher cash and equity after these financings. The company highlights that investing in its ADSs involves a high degree of risk and directs investors to detailed risk factors in its Form 20-F.
Radiopharm Theranostics Limited (RADX) reports that shareholders at a General Meeting on September 11, 2026 approved all resolutions by poll. The resolutions ratified prior issues of First Tranche placement shares and ADS shares, and approved the issue of Second Tranche placement shares, placement attaching options, SPP shares and SPP attaching options, shortfall options, ADR warrants and agent warrants.
Shareholders also approved issues of SPP shares and attaching options to directors Paul Hopper, Ian Turner and Bruce Goodwin, and to Chief Executive Officer and director Riccardo Canevari. Support across all resolutions was high, with poll results generally showing more than 94% of votes cast in favor of each proposal.
Radiopharm Theranostics Ltd (RADX) reported positive initial results from a Phase 1 imaging trial of its radiopharmaceutical candidate RAD301 in healthy volunteers and patients with Pancreatic Ductal Adenocarcinoma. RAD301 targets the αvβ6-integrin receptor using Gallium-68, aiming for more tumor-specific imaging in pancreatic cancer.
The trial showed a favorable safety profile and significant, selective tumor uptake in pancreatic cancer metastases, with low background uptake in liver, lung and bowel, which are common metastatic sites. These data support continued clinical development of RAD301, including a potential Phase 2 imaging trial, and reinforce αvβ6-integrin as a promising diagnostic and therapeutic target. RAD301 has previously received FDA Orphan Drug Designation.
Radiopharm Theranostics Ltd (RADX) is reported to have a significant shareholder group led by Lantheus Omega, LLC, together with Lantheus Medical Imaging, Inc. and Lantheus Holdings, Inc., which collectively beneficially own 792,958,513 Ordinary Shares, or 17.3% of the class. This stake includes (i) 149,625,180 shares issued on August 23, 2024, (ii) 133,333,333 shares issued on January 20, 2025, (iii) 255,000,000 shares issued on December 9, 2025 and (iv) options to purchase 255,000,000 shares at an exercise price of AUD$0.039 per share expiring on October 31, 2027.
The reporting group has no sole voting or dispositive power but may be deemed to share voting and dispositive power over all 792,958,513 shares held of record by Lantheus Omega, LLC. They state that they no longer beneficially own more than 20% of Radiopharm’s outstanding Ordinary Shares and that they do not hold the securities with the purpose or effect of changing or influencing control of the company, changing their reporting posture from a Schedule 13D to a Schedule 13G.
Radiopharm Theranostics Ltd (RADX) discloses that Lantheus Omega, LLC, Lantheus Medical Imaging, Inc. and Lantheus Holdings, Inc. jointly report beneficial ownership of 792,958,513 Ordinary Shares (including options), or 20.9% of the company as of July 27, 2026.
This position consists of 149,625,180 Ordinary Shares acquired on August 23, 2024 at AUD$0.05 per share plus 149,625,180 options at AUD$0.05 (subsequently replaced), 133,333,333 shares acquired on January 20, 2025 at AUD$0.06 per share, and 255,000,000 shares acquired on December 9, 2025 at AUD$0.03 per share, together with 255,000,000 options issued on December 9, 2025 with an exercise price of AUD$0.039 per share expiring October 31, 2027.
The ownership percentage is calculated using 3,544,216,160 Ordinary Shares outstanding as of June 30, 2026 plus the 255,000,000 shares issuable upon option exercise. Lantheus describes this as a strategic investment tied to a $2.0 million upfront asset purchase and three separate $5.0 million private placements and notes potential future purchases or sales of RADX shares depending on market and business conditions.
Radiopharm Theranostics Ltd (RADX) reported a sharp deterioration in results for the year ended 30 June 2026. Revenue from contracts with customers fell 23.8% to $2,767,888, while loss attributable to owners increased 50.3% to $55,149,150, driven mainly by substantially higher research and development spending.
The group’s total loss was $56,950,494 and net assets declined to $22,323,683 from $42,871,904. Cash reserves dropped to $4,138,074 (30 June 2025: $29,116,835) after net operating cash outflows of $52,782,838. Net tangible assets per share were a negative 0.45 cents (2025: negative 0.16 cents), reflecting balance sheet strain.
R&D expenses rose to $49,962,899 (2025: $27,515,194), focused on programs including NanoMab, R&D Ventures, Diaprost and Pivalate – Imperial. Ownership in Radiopharm Ventures, LLC increased to 87.5%. Audited financial statements are expected by the end of September 2026 and are anticipated to include a material uncertainty in relation to going concern. On 24 July 2026 the company announced an institutional offer of A$12.5 million and a A$6 million Share Purchase Plan.
Radiopharm Theranostics Ltd (RADX) reports, via a Form 6-K, that it has furnished to U.S. investors an announcement filed with the Australian Securities Exchange detailing changes in directors’ interests following the expiry of listed options expiring 24 Aug 2026 for four directors. The notices show updated direct and indirect holdings for Riccardo Canevari, Paul Hopper, Ian Turner and Hester Larkin in the company’s shares and options after these listed options expired.